

Curriculum vitae
Vahram Ghushchyan, PhD

Regis University School of Pharmacy
Rueckert-Hartman College for Health Professions
3333 Regis Boulevard, H-28
Denver, CO 80221-1099

w. (303) 964-5487

vghushchyan@regis.edu

Education

PhD in Economics

May 2006

University of Colorado, Boulder, CO, USA.

Department of Economics

Dissertation title: “Econometric Methods for Estimating Health Utility and a Catalogue of Preference-Based Scores for Chronic Diseases”

MA in Economics

May 2001

University of Colorado, Boulder, CO, USA.

Department of Economics

Diploma in Economics with Honors

May 1997

Yerevan State Institute of National Economy, Yerevan, Armenia

EXPERIENCE

Assistant Professor

2021 – Present

Department of Pharmacy Practice

Regis University School of Pharmacy

Professor, Program Chair

2013 – 2021

American University of Armenia, Armenia

Assistant Research Professor

2010 – 2013

Department of Clinical Pharmacy,

Skaggs School of Pharmacy and Pharmaceutical Sciences,

University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Research Associate

2004 – 2010

Department of Clinical Pharmacy,

Skaggs School of Pharmacy and Pharmaceutical Sciences,

University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Conducted Biostatistical and Health Outcomes Research

Teaching and Advising

- Developed and conducted courses in Statistics, Economics, Econometrics and Health Economics
- Supervised Master thesis

Courses offered included:

- Applied Health Econometrics (Limited-Dependent and Qualitative Variables)
- Advanced Econometrics
- Economic Research Seminar
- Data, Analysis and Decisions
- Financial Econometrics and Time Series
- Capstone (master thesis)
- Economic Statistics
- Research Methods

RECENT PUBLICATIONS (PEER REVIEWED 2012-2021)

Author of more than 60 peer-reviewed publications and numerous conference abstracts since 2005.

https://scholar.google.com/citations?user=3_tEoBAAAAAJ&hl=en&authuser=1

Citations as of September 2021	All	Since 2015
Citations	4,399	2,439
h-index	28	23
i10-index	49	46

2021

Complications and Health Care Resource Utilization Associated with Systemic Corticosteroids in Children and Adolescents with Persistent Asthma.

Sullivan PW, **Ghushchyan VH**, Skoner DP, LeCocq J, Park S, Zeiger RS.
J Allergy Clin Immunol Pract. 2021 Apr;9(4):1541-1551.

2020

Impact of allergies on health-related quality of life in patients with asthma.

Sullivan PW, Kavati A, **Ghushchyan VH**, Lanz MJ, Ortiz B, Maselli DJ, LeCocq J.
J Asthma. 2020 Nov;57(11):1263-1272.

Healthcare resource utilization, expenditures, and productivity in patients with asthma with and without allergies.

Sullivan PW, Lanz MJ, **Ghushchyan VH**, Kavati A, LeCocq J, Ortiz B, Maselli DJ.
J Asthma. 2020 Sep;57(9):959-967.

2019

Medication use and indicators of poor asthma control in patients with and without allergies.

Sullivan PW, Lanz MJ, Ghushchyan VH, Kavati A, LeCocq J, Ortiz B, Maselli DJ.
Allergy Asthma Proc. 2019 Jul 3;40(4):221-229.

Association Between Pulmonary Function and Asthma Symptoms.
Sullivan PW, Ghushchyan VH, Marvel J, Barrett YC, Fuhlbrigge AL.
J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2319-2325.

Trends in Asthma Control, Treatment, Health Care Utilization, and Expenditures Among Children in the United States by Place of Residence: 2003-2014.
Sullivan PW, Ghushchyan V, Kavati A, Navaratnam P, Friedman HS, Ortiz B.
J Allergy Clin Immunol Pract. 2019 Jul-Aug;7(6):1835-1842.

2018

The national burden of poorly controlled asthma, school absence and parental work loss among school-aged children in the United States.

Sullivan PW, **Ghushchyan V**, Navaratnam P, Friedman HS, Kavati A, Ortiz B, Lanier B.
J Asthma. 2018 Jun;55(6):659-667.

Health Disparities Among Children with Asthma in the United States by Place of Residence.

Sullivan PW, **Ghushchyan V**, Kavati A, Navaratnam P, Friedman HS, Ortiz B.
J Allergy Clin Immunol Pract. 2018 May 18.

School absence and productivity outcomes associated with childhood asthma in the USA.

Sullivan P, **Ghushchyan VG**, Navaratnam P, Friedman HS, Kavati A, Ortiz B, Lanier B.
J Asthma. 2018 Feb;55(2):161-168.

Oral corticosteroid exposure and adverse effects in asthmatic patients.

Sullivan PW, **Ghushchyan VH**, Globe G, Schatz M.
J Allergy Clin Immunol. 2018 Jan;141(1):110-116.

National Prevalence of Poor Asthma Control and Associated Outcomes Among School-Aged Children in the United States.

Sullivan PW, **Ghushchyan V**, Navaratnam P, Friedman HS, Kavati A, Ortiz B, Lanier B.
J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):536-544.

2017

Indicators of poorly controlled asthma and health-related quality of life among school-age children in the United States.

Sullivan PW, **Ghushchyan V**, Navaratnam P, Friedman HS, Kavati A, Ortiz B, Lanier B.
Allergy Asthma Proc. 2017 Nov 11;38(6):431-439.

Estimating asthma control questionnaire (ACQ) scores from claims data.

Sullivan PW, **Ghushchyan VH**, Globe G.
J Asthma. 2017 Oct 4:1-9.

The national cost of asthma among school-aged children in the United States.

Sullivan PW, **Ghushchyan V**, Navaratnam P, Friedman HS, Kavati A, Ortiz B, Lanier B.
Ann Allergy Asthma Immunol. 2017 Sep;119(3):246-252.

Health-related quality of life associated with systemic corticosteroids.

Sullivan PW, **Ghushchyan VH**, Globe G, Sucher B.
Qual Life Res. 2017 Apr;26(4):1037-1058.

Measuring the cost of poor asthma control and exacerbations.

Sullivan PW, **Ghushchyan VH**, Campbell JD, Globe G, Bender B, Magid DJ.
J Asthma. 2017 Jan 2;54(1):24-31.

2016

Measurement of utility in asthma: evidence indicating that generic instruments may miss clinically important changes.

Sullivan PW, **Ghushchyan VH**, Campbell JD, Globe G, Bender B, Magid DJ.
Qual Life Res. 2016 Dec;25(12):3017-3026.

EQ-5D Scores for Diabetes-Related Comorbidities.

Sullivan PW, **Ghushchyan VH**.
Value Health. 2016 Dec;19(8):1002-1008.

Exploring asthma control cutoffs and economic outcomes using the Asthma Control Questionnaire.

Sullivan PW, Globe G, **Ghushchyan VH**, Campbell JD, Bender B, Magid DJ.
Ann Allergy Asthma Immunol. 2016 Sep;117(3):251-257.e2. doi: 10.1016/j.anai.2016.07.020.
PMID: 27613458
Similar articles

Incremental increases in economic burden parallels cardiometabolic risk factors in the US.

McQueen RB, **Ghushchyan V**, Olufade T, Sheehan JJ, Nair KV, Saseen JJ.
Diabetes Metab Syndr Obes. 2016 Aug 2; 9:233-41.

The cost of inpatient death associated with acute coronary syndrome.

Page RL 2nd, **Ghushchyan V**, Van Den Bos J, Gray TJ, Hoetzer GL, Bhandary D, Nair KV.
Vasc Health Risk Manag. 2016 Feb 3; 12:13-21.

Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives.

Carris NW, **Ghushchyan V**, Libby AM, Smith SM.
J Hum Hypertens. 2016 Mar; 30(3): 191-6.

2015

Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.

Page RL 2nd, **Ghushchyan V**, Read RA, Hartsfield CL, Koch BR 2nd, Nair KV.
Am J Cardiol. 2015 Nov 1; 116(9): 1321-8.

Measuring the effect of asthma control on exacerbations and health resource use.

Sullivan PW, Campbell JD, Globe G, **Ghushchyan VH**, Bender B, Schatz M, Chon Y, Woolley JM, Magid DJ.
J Allergy Clin Immunol. 2015 Nov; 136(5): 1409-11

Outcomes before and after treatment escalation to Global Initiative for Asthma steps 4 and 5 in severe asthma.

Sullivan PW, Campbell JD, **Ghushchyan VH**, Globe G.
Ann Allergy Asthma Immunol. 2015 Jun; 114(6): 462-9.

Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation.

Sullivan PW, Campbell JD, **Ghushchyan VH**, Globe G, Lange J, Woolley JM.
J Asthma. 2015 Sep; 52(7): 669-80.

Comparing clinical effectiveness and drug toxicity with hydrochlorothiazide and chlorthalidone using two potency ratios in a managed care population.

Saseen JJ, **Ghushchyan V**, Nair KV.

J Clin Hypertens (Greenwich). 2015 Feb; 17(2): 134-40.

Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.

Tuchscherer RM, Nair K, **Ghushchyan V**, Saseen JJ.

Am J Cardiovasc Drugs. 2015 Feb; 15(1): 27-34.

2014

Indirect and direct costs of acute coronary syndromes with comorbid atrial fibrillation, heart failure, or both.

Ghushchyan V, Nair KV, Page RL 2nd.

Vasc Health Risk Manag. 2014 Dec 24; 11: 25-34.

Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates.

Campbell JD, **Ghushchyan V**, Brett McQueen R, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J, Miravalle A, Schreiner T, Porter V, Nair K.

Mult Scler Relat Disord. 2014 Mar; 3(2): 227-36.

Hidden costs associated with venous thromboembolism: impact of lost productivity on employers and employees.

Page RL 2nd, **Ghushchyan V**, Gifford B, Read RA, Raut M, Bookhart BK, Naim AB, Damaraju CV, Nair KV.

J Occup Environ Med. 2014 Sep; 56(9): 979-85.

The relationship between asthma, asthma control and economic outcomes in the United States.

Sullivan PW, Slejko JF, **Ghushchyan VH**, Sucher B, Globe DR, Lin SL, Globe G.

J Asthma. 2014 Sep; 51(7): 769-78.

Asthma control in the United States, 2008-2010: indicators of poor asthma control.

Slejko JF, **Ghushchyan VH**, Sucher B, Globe DR, Lin SL, Globe G, Sullivan PW.

J Allergy Clin Immunol. 2014 Jun; 133(6): 1579-87.

2013

Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers.

Saseen JJ, **Ghushchyan V**, Kaila S, Allen RR, Nair KV.

J Clin Hypertens (Greenwich). 2013 Dec; 15(12): 888-92.

Asthma in USA: its impact on health-related quality of life.

Sullivan PW, Smith KL, **Ghushchyan VH**, Globe DR, Lin SL, Globe G.

J Asthma. 2013 Oct; 50(8): 891-9.

The economic burden of acute coronary syndromes for employees and their dependents: medical and productivity costs.

Page RL 2nd, **Ghushchyan V**, Gifford B, Read RA, Raut M, Crivera C, Naim AB, Damaraju CV, Nair KV.

J Occup Environ Med. 2013 Jul; 55(7): 761-7.

Effectiveness and Costs of TNF-Alpha Blocker Use for Patients with Rheumatoid Arthritis.

Nair K, **Ghushchyan V**, Naim A.

Am Health Drug Benefits. 2013 Mar; 6(2): 126-36.

2012

Missed opportunities for providing low-fat dietary advice to people with diabetes.

Lobo IE, Loeb DF, **Ghushchyan V**, Schauer IE, Huebschmann AG.

Prev Chronic Dis. 2012;9: E161.

Association of treatment modality for depression and burden of comorbid chronic illness in a nationally representative sample in the United States.

Loeb DF, **Ghushchyan V**, Huebschmann AG, Lobo IE, Bayliss EA.

Gen Hosp Psychiatry. 2012 Nov-Dec; 34(6): 588-97.

Economic differences in direct and indirect costs between people with epilepsy and without epilepsy.

Libby AM, **Ghushchyan V**, McQueen RB, Slejko JF, Bainbridge JL, Campbell JD.

Med Care. 2012 Nov; 50(11): 928-33.

Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks.

Saseen JJ, Agashivala N, Allen RR, **Ghushchyan V**, Yadao AM, Nair KV.

Rheumatology (Oxford). 2012 Nov; 51(11): 2004-12.

Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap.

Page RL 2nd, **Ghushchyan V**, Allen RR, Roper L, Beck D, Jonathan BH, Frech-Tamas F, Chan W, McQueen RB, Nair KV.

Drug Healthc Patient Saf. 2012; 4: 67-74.

The impact of co-morbidity burden on preference-based health-related quality of life in the United States.

Sullivan PW, **Ghushchyan VH**, Bayliss EA.

Pharmacoeconomics. 2012 May; 30(5): 431-42.

Burden of illness for an employed population with chronic obstructive pulmonary disease.

Nair K, **Ghushchyan V**, Van Den Bos J, Halford ML, Tan G, Frech-Tamas FH, Doyle J.

Popul Health Manag. 2012 Oct; 15(5): 267-75.